Where does Wyvern Pharmaceuticals Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Wyvern Pharmaceuticals Inc. ranks #12,768 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Wyvern Pharmaceuticals Inc. hold?

Wyvern Pharmaceuticals Inc. holds 24 US utility patents granted between 2022 and 2025, spanning 5 technology areas.

What is Wyvern Pharmaceuticals Inc.'s Innovation Score?

Wyvern Pharmaceuticals Inc. has an Innovation Score of 43.4 out of 100 (top 28% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Wyvern Pharmaceuticals Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Wyvern Pharmaceuticals Inc..

What does claim depth mean for Wyvern Pharmaceuticals Inc.'s patents?

Wyvern Pharmaceuticals Inc.'s patents average 7.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Wyvern Pharmaceuticals Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Wyvern Pharmaceuticals Inc.

Q: What technology areas does Wyvern Pharmaceuticals Inc. focus on?

Wyvern Pharmaceuticals Inc.'s top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 23 patents, ranking #461 of 4,144 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

USPTO PatentsView assignee record - 24 granted patents across 5 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Wyvern ranks #12,768 of 49,997 tracked US assignees by granted-patent volume, with 24 patents across 5 technology areas.

#12,768
of 49,997 US assignees by volume: Top 28%
by Innovation Score (43.4/100): 7.3
avg claims per patent

USPTO PatentsView assignee plate

Corpus R12768 · Foreign Corporation #12,768 · 24 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-SPARSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 24 grants
MID-PACK #12,768/49,997
PHOTO-FINISH Workshops for Warriors
CPC-NARROW C12N · 5 areas
INNOV-PAR 43.4/100
CLAIMS-SPARSE 7.3 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Workshops for Warriors (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Wyvern’s 43.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.1 pts (26%) Velocity 20.0 pts (46%) Breadth 7.9 pts (18%) Claim depth 4.4 pts (10%)

Qualcomm Incorporated · highest

85
Wyvern Pharmaceuticals · this assignee

43
3D Lighting… · lowest

7

What this shows Wyvern's Innovation Score is 43.4/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Wyvern?

Each dot is one of Wyvern’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Wyvern’s own 7.3 claims/patent is ABOVE the 7.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Wyvern vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Wyvern's grants concentrate

Wyvern Pharmaceuticals Inc. is a focused PatentsView assignee: 5 CPC subclasses with 95.8% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2022. By volume, Wyvern sits between Workshops for Warriors and Yvolve Sports Limited.

Wyvern's three-year grant acceleration

Wyvern Pharmaceuticals Inc. shows 6 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Workshops for War…

24
Worthington Cylin…

24
Wudi Industrial (…

24
Wuhan Telecommuni…

24
Xbiotech

24
Xiamen Sunnypet P…

24
Xactly

24
Yvolve Sports

24
Wyvern Pharmaceut… ◀

24

What this shows Wyvern holds 24 patents at rank #12,766, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Wyvern

By rank, the assignees closest to #12,766 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Wyvern's primary technology class.

Wyvern's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 28% higher than 72% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Wyvern Pharmaceuticals Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	1	4.2%
2023	1	4.2%
2024	4	16.7%
2025partial year	18	75.0%

Which technologies does Wyvern Pharmaceuticals Inc. patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 23

C07K - Peptides 15

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 2

C12Y - Enzymes 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Wyvern Pharmaceuticals Inc.'s patent record in context - here's where to go next.

Wyvern Pharmaceuticals Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 95.8% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #12,768 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Wyvern Pharmaceuticals Inc. against Workshops for Warriors, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.